This is a five-arm designed to assess the safety of L1-79 that incorporates 15 prospectively
randomized, placebo controlled patients and 5 open label patients at either 100 tid or 200
tid dosing for 28 days. The open label patients will be assessed for the purpose of
understanding PK/PD and to determine if there are any EKG changes associated with the
administration of L1-79. Additional safety information will be provided by the 30 patients
randomized 2:1 active:placebo.